直 Japanese PDF Font
  • Our Professionals
  • Our Work
  • Our Insights
  • Offices
  • Firm
  • Careers
Finnegan
  • News
  • Finnegan Facts
  • History
    • Finnegan VISION
    • Finnegan FORWARD
  • Pro Bono
  • Management
    • Pricing & Alternative Fee Arrangements
    • AFA Models We Offer
    • Contingency Fees
    • AI + KM

Media Mention

Ex-PTAB Judges Say Board Policies Don't Squelch Dissents

June 11, 2018

Law360

Dissenting opinions are rare at the Patent Trial and Appeal Board (PTAB), but former judges explain that it's not because the Board feels discouraged by officials to offer dissenting opinions, but it's because the Board strives to reach a consensus. Law360 interviewed Finnegan partner Trenton Ward--a PTAB judge from 2012-2017--to discuss dissenting opinions at the PTAB.

Trenton said, "In my mind, there is not discouragement from management of individuals writing dissents and concurrences. I'm not aware of situations where judges did not receive credit for writing a concurrence or a dissent." He went on to say, "The goal of the judges is to reach a consensus with respect to the outcome. Often there are multiple avenues to reach an outcome, and to the extent the panel can choose one that all members agree on, that's often the path that's chosen." He also noted that while the PTAB's decisions are often unanimous and written by one judge, all members of the panel are involved in the decision-making process, which he found to be extremely beneficial.

Tags

dissent

Related Practices

Patent Office Invalidation Proceedings

Related Offices

Atlanta, GA

Related News

Commentary

New Appellate Opinion in Amazon Biometric Data Case May Signal ‘Narrowing’ Scope of BIPA Litigation, Experts Say

May 20, 2026

Commentary

ITC Bars Import of Innoscience Chips Made Before Redesign

May 8, 2026

Commentary

How Litigation Funding Disclosure Could Affect ITC Cases

May 7 , 2026

Award/Ranking

Associates Rank Finnegan “Best of the Best” in BTI Associate Satisfaction Survey

May 7, 2026

Award/Ranking

61 Finnegan Attorneys Recognized on the 2025 Capital Pro Bono Honor Roll

May 7, 2026

Commentary

Justices to Side with Generic Drugmakers in Patent Spat, Attorneys Predict

May 5, 2026

Announcement

Finnegan Partner Ningling Wang Becomes President of Licensing Executives Society International

May 4, 2026

Award/Ranking

Finnegan Wins IP Firm of the Year at the 2026 LSPN Awards

May 1, 2026

Commentary

Supreme Court Takes Up Generic Drug Labeling Fight

April 29, 2026

Due to international data regulations, we’ve updated our privacy policy. Click here to read our privacy policy in full.

  • Privacy
  • Disclaimer
  • Legal Notices
  • Fraud Alert
  • EEO Statement
  • Cookies
  • Contact Us

© 2026 Finnegan, Henderson, Farabow, Garrett & Dunner, LLP